News

Drug target review@4x

Scenic’s Vincent Blomen in Drug Target Review

Scenic Biotech Enters Cooperative Research and Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease

Scenic Biotech Strengthens Drug Discovery Expertise in Management Team with the Addition of Kristof Van Emelen

Scenic Biotech Appoints Jens Würthner as Chief Medical Officer

Picture website

Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to Find Tailored Treatment for the Complex Rare Disease

1. scenic biotech genetic modifier image 1

Proof of concept in preclinical models for the use of QPCTL inhibition

Rene van den oever

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases

Genbanner ecp green i

Biocentury features an emerging company profile on Scenic Biotech

Sebastian Nijman presenting at BioTrinity 2021

Rene van den oever

Scenic Biotech and Genentech expand their Genetic Modifier Partnership

Phillipe dro (1)

Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman

Ton Schumacher, member of Scenic’s Scientific Advisory Board has been awarded the Jeantet-Collen Prize for Translational Medicine